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Prostate cancer is the second most often diagnosed cancer and internationally the sixth 
foremost cause of cancer death in males, as of 2011.  Within the United States it is the most 
common form of cancer in men with 186,000 new cases and with an overall 28,600 deaths in 
2008, and it is the second leading kind of cancer-related death in men. The widespread threat that 
prostate cancer poses against men across the globe cannot be understated, and its initiation and 
progression must be understood in order to truly comprehend its implicated risks and possible 
forms of treatment.  
As its name implies, prostate cancer is a form of cancer that develops in the prostate 
gland located in the male reproductive system. Its progress starts when standard semen-secreting 
prostate gland cells mutate into cancer cells. Although its developments may start at the prostate 
gland, cancer cells may metastasize to other parts of the body through circulation systems such 
as the lymph nodes. The main sites of metastasis for prostate cancer include the adrenal gland, 
the bones, the liver and the lungs.  
Although there are treatments available for prostate cancer, there is no definitive cure. 
The primary goal of this project was to find an alternative form of treatment, which is what will 
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Events with Implications on Prostate Cancer Initiation 
One of the most important prostate cancer risk factors is increasing age, and several 
studies have linked aging to changes in overall gene expression, such as those included in 
inflammation, oxidative stress, and cellular senescence.       
 There is support that indicates a link between chronic inflammation and prostate cancer 
carcinogenesis, and expression of particular chemokines has been known as a predictor of 
biochemical disease recurrence in human prostate cancer (Begley, Monteleon et al. 2005). An 
example of this was shown by the administration of the heterocyclic amine PhIP in rodents, 
which caused chronic inflammation and promoted prostatic hyperplasia and prostatic 
intraepithelial neoplasia (PIN), which is a premalignant stage that is closely associated with 
cancer (Elkahwaji, Zhong et al. 2007). Also, the well-studied gene GSTP1 is known to detoxify 
reactive carcinogens such as PhIP, and it has been shown to be silenced as a result of DNA 
methylation in various prostate cancers (Nakayama, Gonzalgo et al. 2004).   
 Oxidative stress and its potential in causing DNA damage are also significant factors that 
may contribute to prostate carcinogenesis. This stress comes from a disproportion of reactive 
oxygen species and enzymes that regulate their levels (Shen and Abate-Shen 2010). Studies have 
shown a reduction in antioxidant enzymes in human PIN and prostate cancer along with an 
increase in the oxidized DNA adduct 8-oxy-dG (Bostwick, Alexander et al. 2000). The NKX3.1 
gene is often downregulated in the initial stages of prostate cancer, and this may contribute to 
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DNA damage due to oxidative stress, since loss of function of the Nkx3.1 homeobox in rodent 
prostate has been shown to lead to a decrease in expression of oxidative damage response genes 
and amplified levels of 8-oxy-dG (Ouyang, DeWeese et al. 2005).     
 Cellular senescence has also been studied in relation to prostate carcinogenesis and its 
transition from a latent stage to the more aggressive clinical stage. Cellular senescence refers to a 
type of cell cycle arrest in which cells maintain their viability but remain in a nonproliferative 
state even in the presence of mitogenic signals. Studies have shown that cellular senescence may 
contribute as a form of tumor suppression that thwarts the progression to a malignant state. For 
instance, complete inactivation of the tumor suppressor gene known as Pten results in prostatic 
intraepithelial neoplasia lesions that exhibit a senescence phenotype (Chen, Trotman et al. 2005). 
This phenotype may be bypassed by the inactivation of the p53 tumor suppression gene, which 
indicates that extra oncogenic occurrences are most likely necessary to overcome senescence 
(Chen, Trotman et al. 2005).  
Molecular Basis for Prostate Cancer Development 
Several molecular mechanisms play a potential role in the initiation or advancement of 
prostate cancer, some of which have already been mentioned. The upregulation of the human 
oncogene MYC has been known to be amplified in some advanced forms of prostate tumors, and 
more recently the MYC protein has been shown to be overexpressed in PIN lesions and in 
several carcinomas, which suggests that elevated levels of nuclear MYC may be a significant 
oncogenic incident for initiation of prostate cancer (Gurel, Iwata et al. 2008).   
 MiRNA expression in relation to the progression of prostate cancer has also been studied, 
and in addition to regulating normal cell functions miRNAs have been found to play a role in 
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regulating pathogenic cancer processes. For instance, miRNAs have been shown to be involved 
in precise regulation in the expression of target genes such as the previously mentioned Pten, 
which has been revealed to be negatively regulated by the miRNA-106b-25 (Poliseno, Salmena 
et al. 2010). Another example is the miRNA-101, which has been found to inhibit the expression 
and function of EZH2, a histone methyltransferase associated with aggressive tumors that has 
been found to play a role in the epigenetic silencing of target genes and in the regulation of 
cancer cell metastasis (Varambally, Cao et al. 2008).      
 The alteration of intracellular signaling pathways in prostate cancer cell progression has 
also been observed. Simultaneous activation of the signaling pathways known as Akt/mTOR and 
Erk (p42/44) MAPK stimulates tumor progression and castration resistance in prostate cancer 
cell lines and mouse models (Kinkade, Castillo-Martin et al. 2008). Simultaneous inhibition of 
each has been shown to hinder castration-resistant prostate cancer in genetically engineered 
mice, suggesting the possibly important role that these pathways play together (Kinkade, 
Castillo-Martin et al. 2008).    
Current Prostate Cancer Treatments 
 Various forms of treatment are available to treat prostate cancer and current cancer 
treatment takes into consideration the age and expected lifespan of the patient, the stage and the 
grade of cancer, the patient’s health conditions, the probability that the chosen treatment will 
cure the cancer, the possible side effects of the specific form of treatment, and the overall 
opinions of the patient and doctor of the need for treatment. Frequently, before any forms of 
treatment are administered, physicians may suggest taking a period of watchful waiting, during 
which the progression of the prostate cancer is regularly checked. If a prostatectomy is not a 
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viable form of treatment (which may be due to the development of a late stage form of cancer 
that has spread to other areas), other current treatment that may be used include chemotherapy, 
radiation therapy, and hormone therapy.  
Chemotherapy 
Chemotherapy treatments involve the injection or oral consumption of anti-cancer drugs 
and as a result they are generally utilized in cases that involve metastatic spread of cancer 
through the bloodstream. One of the primary drugs used in chemotherapy is Docetaxel, a taxane 
(a drug that comes from a plant of the genus Taxus) which interferes with cancer cell division. 
The mechanism of action used by docetaxel involves inhibition of mitotic cell division between 
metaphase and anaphase through the suppression of microtubule assembly and disassembly 
(halting cancer cell division), and an accumulation of microtubules inside cells which may result 
in the initiation of apoptosis (Lyseng-Williamson and Fenton 2005). Docetaxel has been shown 
to slow metastatic cancer progression and studies have shown significant survival benefit from 
this drug in androgen-independent metastatic prostate cancer (Tannock, de Wit et al. 2004).
 Nevertheless, many adverse effects have been associated with docetaxel treatment, such 
as its cytotoxicity to all dividing cells in the body. Side effects include cytotoxicity to the hair 
follicles and the bones marrow, and even hematological effects such as neutropenia, anemia, and 
thrombocytopenia, which can make patients more prone to infections and overall weakness and 
fatigue (Lyseng-Williamson and Fenton 2005).       
 Cabazitaxel, also a microtubule inhibitor and a taxane, is often a drug used for treatment 
after docetaxel. Just like docetaxel, it has also shown to cause common adverse effects such as 
anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting and 
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constipation (Abidi 2013).           
 Docetaxel and cabazitaxel have been more recently utilized for prostate cancer treatment, 
and mitoxanthrone is generally used as a second line of treatment since it does not offer the 
improved survival and disease free period as these latest forms of treatment. Mitoxanthrone is a 
type II inhibitor of topoisomerase and disrupts DNA synthesis and repair (Mazerski, Martelli et 
al. 1998). A study showed a palliative response when treated along with prednisone against 
hormone-resistant prostate cancers in 23 of 80 randomized patients, and an improvement in 
quality-of-life scales and a decrease in serum prostate-specific antigen level, which is often 
increased in patients with prostate cancer (Tannock, de Wit et al. 2004). Mitoxanthrone only 
serves as a drug whose treatment can result in palliative responses and not as a definitive cure, 
and the main goal of its treatment is to improve the quality of life of the patient. In addition to 
this, mitoxanthrone treatment may cause adverse effects with varying severity such as 
cardiomyopathy, nausea, vomiting, hair loss, immunosuppression and heart damage, which may 
result from the fact that it may affect both cancerous and healthy cells in the body (Fox 2006).  
Radiation Therapy 
Radiation therapy for prostate cancer involves treatment of cancer cells with high energy 
rays such as x-rays to kill them or to reduce the size of tumors. Two different types of radiation 
methods may be used, External beam radiation therapy (EBRT), radiation which comes from 
outside of the body, or internal radiation from radioactive materials inserted into the tumor, 
which is also known as brachytherapy.       
 Standard EBRT is not frequently used currently due to its substandard level of accuracy 
compared to newer techniques, which has been known to cause undesired exposure of nearby 
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tissues to radiation. EBRT is also only able to be primarily used in more localized stages of 
prostate cancer, and even in these cases has been shown to result in transitional cell carcinoma of 
the bladder, which is more aggressive and its diagnosis may occur later due to the fact that some 
radiation oncologists believe that the hematuria occurring after this treatment is considered to be 
common (Suriano, Altobelli et al. 2013). Some patients treated for localized forms of prostate 
cancer may end up having invasive bladder cancer that requires surgical treatment (Suriano, 
Altobelli et al. 2013). Many other adverse effects have been associated with EBRT patients, such 
as bowel problems, fatigue, bladder problems, urinary incontinence, erection dysfunction, 
urethral stricture, and lymphedema. Brachytherapy is a more common form of radiation 
treatment due to its fewer serious side effects, and its more specific localization, which focuses 
radiation exposure to the prostate rather and limits other nearby tissue exposure (Zaorsky, Doyle 
et al. 2013). A 2007 study observing patient quality life showed brachytherapy as a more 
favorable form of treatment, as opposed to treatments such as EBRT and prostatectomy (Buron, 
Le Vu et al. 2007). Brachytherapy as a form of treatment is only useful for localized forms of 
prostate cancer, since it requires the insertion of tiny radioactive particles into a tumor site, and 
therefore would not be useful for treating more advanced forms of prostate cancer involving 
metastasis, which may have been diagnosed too late.  
Hormone Therapy 
Various types of hormone therapies exist, and most involve direct or indirect deprivation 
of the androgens dihydrotestosterone (DHT) and testosterone, which stimulate the growth of 
prostate cancer cells. Several methods may be used in androgen deprivation therapy, such as 
orchiectomy (removal of testicles to prevent androgen production), luteinizing hormone-
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releasing hormone (LHRH) agonists and antagonists (which chemically reduce the level of 
androgen production by the testicles), and anti-androgens, which block the androgen receptors on 
prostate cells. A major problem with hormone therapy is the lack of consensus regarding the best 
time to begin and to cease treatment. There are several opinions and current studies regarding the 
advantages and disadvantages of early deprivation therapy treatment versus delayed treatment, 
and continuous versus intermittent treatment, and definitive answers regarding the most effective 
methods are yet to be seen (Trendel 2013).        
 Unfortunately, many hormone dependent cancers such as prostate cancer become 
refractory after one to three years and continue to grow even with androgen deprivation. This 
type of development is known as castration-resistant prostate cancer due to the cancer cells’ lack 
of response to the surgical or chemical reduction of androgen. Once this occurs, 
chemotherapeutic drugs such as docetaxel may be provided as treatment.   
 Since each form of hormone therapy affects the action of androgen on its receptor and 
ends in a similar result, through surgical or chemical removal of the source of androgen or by the 
direct blocking of its receptor, many adverse side effects are shared as a result of the reduction of 
testosterone or DHT. Changes in the level of androgen may also include changes in estrogen 
levels, and side effects may include a reduced libido, impotence, the shrinking of the testicles 
and penis and gynecomastasia. More serious side effects that stem from androgen deprivation 
include anemia, osteoporosis, loss of muscle mass, fatigue, increase cholesterol, decreased 
mental sharpness, and depression (Miwa, Mizokami et al. 2013).  
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Potential Forms of Treatment 
Antimitotics 
Many different types of inhibitors have been and are currently being studied to treat 
prostate cancer. As previously mentioned, docetaxel is a chemotherapeutic drug and an inhibitor 
of mitosis that works by binding to microtubules, subsequently preventing cell division. A major 
focus of chemotherapeutics has recently been placed on antimitotic drugs such as docetaxel due 
to the fact that cancer is a disease of unrestrained mitosis. However, instead of focusing on 
microtubules as the major targets to halt mitosis, recent research has focused on targeting 
proteins that play a major role in mitotic events in order to prevent possible binding to 
microtubules of non-tumorigenic cells. These target proteins include kinases and kinesins. 
Aurora Kinase Inhibition  
The serine/threonine kinases known as Aurora have been known to have three types: Aurora A, 
Aurora B, and Aurora C. Aurora A plays a role in mitotic spindle assembly during the early 
stages of mitosis, and its inhibition can lead to mitotic arrest and eventually apoptosis as a result 
of faulty spindle morphology. Aurora B and Aurora C play a role in later stages of mitosis and 
especially in cytokinesis, and inhibition of Aurora B can lead to the prevention of cytokinesis, 
polyploidy and then apoptosis.         
 This family of kinases has been shown to be overexpressed in cancer cells, and have 
therefore been targeted in recent developments (Wissing, van Diest et al. 2013). One of the first 
aurora kinase inhibitors to enter clinical trials was VX680, which has been shown to inhibit each 
of these three kinases in vitro with IC50 values ranging from 15 to 130 nM (Jeet, Russell et al. 
2012). Even with its promising results, its clinical trials were suspended due to toxicity values. 
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Another inhibitor under study is AZD1152, an inhibitor of Aurora B that is currently undergoing 
phase 2 clinical trials, and so far has been shown to be reasonably well tolerated for the treatment 
of diffuse large B-cell lymphoma, although side effects such as stomatitis and suppression of the 
bone marrow have been observed (Jeet, Russell et al. 2012). Another promising candidate in 
current drug developments is MLN8237. MLN8237 is an Aurora A kinase inhibitor that is also 
presently undergoing phase 2 clinical trials, and it has been reported to have high specificity and 
potency as an inhibitor of Aurora A, with an IC50 value of 1 nM (Jeet, Russell et al. 2012).
 There are many more aurora kinase inhibitors that have or are currently undergoing 
clinical trials, and aurora kinases appear to be very promising as targets for the disruption of 
mitosis.  
Polo-Like Kinase Inhibition 
Polo kinases (PLKs) have also been targeted in recent anticancer drug developments. 
These are a family of serine/threonine kinases that are involved in the generation of spindle 
poleward pulling forces and cytokinesis, and PLK1, one of the four members of this family, has 
been shown to be elevated in many tumors (Harrison, Holen et al. 2009). One promising 
distinction in regards to these kinases as possible targets is that the inhibition of PLK1 has been 
shown to lead to a G2/M arrest and apoptosis (Warner, Gray et al. 2006). In addition, while 
PLK1 depletion has been shown to be harmful to cancer cells, normal cells have displayed little 
to no cytotoxicity in response to this treatment, thus making it a desirable target in antimitotic 
cancer research (Liu, Lei et al. 2006).        
 One promising compound in polo-like kinase inhibition is BI2536, a highly specific 
inhibitor of PLK1. A phase 1 clinical trial with 21 patients with advanced solid tumors showed 
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the maximum dosage of this compound to be 60 mg, which was determined based on dose-
limiting toxicities (Harrison, Holen et al. 2009). The most commonly reported side effects 
included fatigue, leukopenia, constipation, nausea, mucosal inflammation, anorexia, and 
alopecia. This drug is currently undergoing phase 2 trials involving metastatic or relapsed non-
small cell lung cancer.         
 Another polo-like kinase inhibitor is ON01910.Na, an ATP noncompetitive inhibitor of 
PLK1 that hinders ability of PLK to bind substrates. This compound is currently undergoing 
Phase 3 studies involving the treatment of metastatic pancreatic adenocarcinoma (Harrison, 
Holen et al. 2009). 
Kinesin Spindle Protein Inhibition  
Kinesin spindle proteins are motor proteins that play a role in bipolar spindle formation 
and centrosome separation. It has been shown that expression of kinesin spindle proteins is 
elevated in tumor cells, and inhibition of these proteins has displayed mitotic arrest due to the 
formation of a monopolar spindle (Harrison, Holen et al. 2009). Ispinesib is a compound that 
inhibits kinesin spindle protein ATPase via uncompetitive inhibition with ATP and ADP. It has 
shown activity in patients with metastatic breast cancer in phase 2 clinical trials, but has not 
shown activity in other cancers such as ovarian and colorectal cancers (Harrison, Holen et al. 
2009).             
 Other compounds that practice kinesin spindle protein inhibition and are currently 
undergoing trials are SB-743921 and GSK-923295. SB-743921 has shown even more potency 
than ispinesib and is currently undergoing phase 1 and 2 trials in non-Hodgkin’s lymphoma 
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(Harrison, Holen et al. 2009). GSK-923295 is currently undergoing phase 1 trials in patients with 
advanced solid tumors and refractory cancer (Harrison, Holen et al. 2009).  
Drug Discovery: An Observation of Natural Compounds 
Numerous possible forms of treatment for diseases such as cancers have been discovered 
through synthetic combinatorial chemistry. Recently, however, many drug discovery programs 
have been focusing on natural compounds in their research efforts. Some of the main problems 
that have been associated with the utilization of naturally-derived compounds in drug discovery 
and have therefore retarded its process involve difficult screening procedures, some of which 
include the presence of impure samples which contain mixtures rather than a single compound 
and the possibility of product degradation. Efforts with pure combinatorial synthetic chemistry 
have also met with some failure in the last two decades with high throughput screening. This 
process has resulted in the production of millions of molecules via random generation of 
compound libraries that have not effectively met the requirements of the drug discovery industry.
 These main problems associated with working purely with naturally-derived compounds 
or synthetically-derived compounds have been under study. One recent manner of overcoming 
these problems, which has already been applied by several research groups, is to look into 
utilizing natural compound structures as starting points in the development of drug-like libraries. 
This approach allows drug discovery programs to utilize the advantages that come from each of 
these methods while avoiding the complications that usually come with their isolated execution.  
 One complication in the implementation of this combined approach has been translating 
the inherent complexity of natural products into a manageable form of chemistry. One manner of 
overcoming this unique dilemma has been to investigate simple structural elements that 
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commonly occur in natural products. The BioCore has been identified by the company ASINEX 
as one of these elements, and its structure consists of two heterocycles, one aromatic and one 
saturated, that are linked by a carbon-carbon bond or a carbon-carbon linear spacer fragment 
(Kombarov, Altieri et al. 2010). The concept of the BioCore was obtained from a statistical 
analysis of known drugs and natural products and it may solve some of the complications that 
come from designing small molecule scaffolds from complex natural products (Kombarov, 
















 Three types of cell lines were utilized for this study: PC-3 cells, BPH-1 cells, and NIH-
3T3 cells. PC-3 cells are an aggressive prostate cancer cell line that have high metastatic 
potential. BPH-1 cells are benign prostatic hyperplasia cells, which are immortalized cells that 
are not metastatic, and NIH-3T3 cells are standard fibroblast cells. PC-3 cells were maintained in 
HAM media (Gibco), supplemented with 10% heat-inactivated fetal bovine serum (Atlanta 
Biologicals), 1% antibiotic-antimitotic, and 1% L-Glutamine. BPH-1 cells were maintained in 
phenol red-free Dulbecco’s Modified Eagle’s Medium media (Sigma-Aldrich), supplemented 
with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals), 1% antibiotic-antimitotic, 
and 1% L-Glutamine. NIH-3T3 cells were maintained in phenol red-free Dulbecco’s Modified 
Eagle’s Medium media (Sigma-Aldrich), supplemented with 10% heat-inactivated fetal bovine 
serum (Atlanta Biologicals), 1% antibiotic-antimitotic, and 1% L-Glutamine. All cells were 
maintained in a 5% CO2 humidified incubator at 37
oC. 
Cell Seeding 
 The three cell lines that were previously mentioned were seeded in 384-well plates. 
Approximately 500 PC-3 cells were seeded per well, approximately 500 BPH cells were seeded 
per well, and approximately 200 3T3 cells were seeded per well. All cell lines were maintained 
in 20 cm tissue culture plates, and cells were washed with 3 mL of 1X PBS, then 3 mL of 1X 
trypsin was added to each tissue culture plate and maintained at room temperature for 
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approximately 30 seconds, then trypsin was removed and the tissue culture plate was incubated 
at 37oC with 5% CO2 for approximately 10 minutes. All cells were then resuspended in their 
respective media, and 20 uL of this cell-media mixture was added to each well in a 384-wel 
plate.  
Compound Dilution Preparation 
 The compounds used in this experiment were obtained from a library that included 511 
ASINEX compounds whose structures are derived from the concept of the BioCore. Each 
compound was resuspended in DMSO solvent in a glass vial at a concentration of 10mM and 
stored at -80oC. For each day of treatment of cells with these compounds, each compound was 
thawed at room temperature, vortexed for 2 minutes, and added to the cell line’s respective 
media in a microcentrifuge tube, which was then also vortexed for 2 minutes.  
Compound Treatment 
 20uL of compound-media solution was added to each well in a 384 well plate for a total 
volume of 40uL in each well for each cell line after treatment. Each plate was incubated for 72 
hours. 
MTS Assay and Absorbance Readings 
 In addition to qualitative microscopy analysis, inhibition of cells was quantified via an 
MTS assay after the 72 hour time point. The MTS assay is a cell viability assay that allows for 
the measurement of the relative number of living cells in culture. MTS is a tetrazolium salt that is 
converted into formazan by dehydrogenase enzymes found in metabolically active cells. The 
amount of formazan product measured at a 490nm absorbance is directly proportional to the 
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number of living cells in culture. In addition to 490nm readings, background absorbance 
readings were also collected at 620nm and subtracted from the initial 490nm values to obtain 
values that are not affected from chemical interference from other compounds that may be 
present in the media. 8uL of MTS was added to each well in this experiment, in relation to the 
amount of total media in each well which was 40uL. After MTS assay dye was added, for each 
plate treated in this experiment, the cells were incubated for four hours. Then each plate was 
scanned for absorbance values by using a multifunctional plate reader (Biotek) and then values 
were compared to the DMSO control values in order to detect inhibition. 
Data Analysis 
511 compounds were initially screened at 10µM in triplicate using PC-3, BPH, and 3T3 
cells. Those compounds with which we observed high percentage of inhibition of PC-3 cells and 
lower percentages of inhibition of the other cell lines were tested at again at 10µM and at lower 
concentrations, specifically at 5µM, 2.5µM, 1.25µM, and 0.625µM. For each cell line, the 
average of the triplicate 490nm-620nm triplicate absorbance values at the initial screening of 
10µM were calculated and divided by the DMSO-only treated cells to produce a ratio to control. 
The controls included live cells with the same total amount of media, DMSO-only treated cells, 
and dead cells treated with 50% tween. The absorbance values for these controls were also 
included in the ratio over the vehicle (DMSO-only treated cells). These ratios were calculated 
and displayed in graphical form.  
These ratios were also organized into a visualized heat map through the use of Gene 
Cluster 3.0. This clustering program provides methods to determine similarities between 
different values (such as Euclidean distance, which was utilized in this experiment) and it 
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provides multiple hierarchical clustering options (such as complete linkage clustering, which was 
utilized in this experiment) (de Hoon et al., 2004). In order to create a visualized heat map, the 
ratios were processed in log space (in log base 2 for simplicity). This means, for example, that 
any 2-fold changes up or down from an initial data point are symmetric about 0. The data was 
then normalized and the Euclidean distance and complete linkage clustering methods were taken 
into account. The Euclidean distance takes the magnitude of changes in inhibition levels into 
account and complete linkage clustering makes the distance between two items a and b the 
maximum of all pairwise distances between items contained in a and b. This analysis was then 
visualized as a heat map with Java Treeview (Page, 1996). 
Percent inhibition is a value demonstrating the percentage of cells that were inhibited per 
well. The percentage of inhibition was calculated for each compound and for each cell line. This 
was obtained by utilizing the values from the 490nm-620nm absorbances that were read in 
triplicate per compound. To calculate percent inhibition per well, the absorbance reading from 
each compound-treated well was subtracted from the average absorbance reading for DMSO-
only treated cells from the respective cell line from triplicate values in each plate. This value was 
then divided by a second value, which was the average absorbance calculated for the dead cell 
wells in triplicate from the same cell line subtracted from the same average absorbance reading 
for DMSO-only treated cells. This total value was then multiplied by 100 to obtain the final 
percent inhibition. 
 After percent inhibition was calculated for each compound out of the 511 compounds that 
were screened, the values were sorted based on the highest inhibition percentage values obtained 
from treated PC-3 cells, since one of the primary goals of this procedure was to acquire possible 
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inhibitors of aggressive prostate cancer cells by utilizing PC-3 cells as a model. There were two 
tiers of compounds that were sought after in the initial screening in order to conduct further tests: 
those with high levels of inhibition of PC-3, low levels of inhibition of BPH, and low levels of 
inhibition of NIH-3T3 cells, and those with high levels of inhibition of PC-3, high levels of 
inhibition of BPH-1, and low levels of inhibition of NIH-3T3 cells. The former tier was the most 
favorable because it would resemble a compound with the ability to inhibit aggressive prostate 
cancer cells while maintaining viable BPH-1 (unaggressive cancer cells) and 3T3 cells (which in 
this case model normal cells of the human body). The second tier of compounds would resemble 
an inhibitor of both aggressive and unaggressive prostate cancer, and thus would not be as highly 
sought after due to this decreased specificity of inhibition. 
 Nine compounds were placed in one of these tiers out of the initial screening at 10µM. 
Four were placed in the first tier and five in the second tier. These nine compounds were tested 
again at the original concentration of 10µM, and at four lower levels of concentration: 5µM, 
2.5µM, 1.25µM, and 0.625µM.  
 IC50, or half maximal inhibitory concentration, is a measurement used to measure the 
effectiveness of a compound’s inhibition ability. It indicates the minimum concentration that is 
needed for a compound to inhibit biological functions by half. The IC50 values for each of these 
nine compounds was calculated by using their observed absorbance values at the five previously 
mentioned concentrations through the use Graphpad PRISM and were obtained by normalizing 
them to the controls. The lowest IC50 values will be used to conduct further studies about the 
effectiveness of inhibition of these drugs. 
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 The Lipinski Rule of Five was then utilized to determine the potential that these 
compounds have as potential oral drugs by utilizing the computer program MarvinSketch 
(Chemaxon). This method is used as a rule of thumb to determine if a compound can be used as 
an orally active drug in humans by analyzing the molecular structure of the compound (Lipinski, 
Lombardo et al. 2001). This method takes into account factors such as the number of hydrogen 











Initial 10µM Screening 
The following graphs show the values obtained from the initial 10µM screening of 511 
compounds over 72 hours. This was conducted by using the MTS assay. Each graph represents a 
plate with different absorbance average values which were normalized to the DMSO-only treated 
controls. In each graph, the red bars represent PC-3 cells, the blue bars represent BPH-1 cells, 
and the yellow bars represent NIH-3T3 cells. Each cell line has its own controls: live cells, dead 






Figure 1: Compounds 5a1 through 5c10 
Figure 1 shows an initial screening of compounds 5a1 through 5c10 at 10µM with DMSO treated cells, live cells, and 
dead cells as controls. 
In Figure 1, compound 5b7 was noted as a candidate for the next screening at lower concentrations due to its lower 







Figure 2: Compounds 2a2 through 2d7 
Figure 2 shows an initial screening of compounds 2a2 through 2d7 at 10µM with DMSO treated cells, live cells, and 




Figure 3: Compounds 2d9 through 2h1 
Figure 3 shows an initial screening of compounds 2d9 through 2h1 at 10µM with DMSO treated cells, live cells, and 





Figure 4: Compounds 3a1 through 3d1 
Figure 4 shows an initial screening of compounds 3a1 through 3d1 at 10µM with DMSO treated cells, live cells, and 




In Figure 4, 3a3 was ruled out as a candidate for the next screening due to its low 3T3 
ratio in comparison to its live ratio, which suggests that this compound may be harmful to 
normal cells. 3c1 was noted as a candidate because of the proximity of its NIH-3T3 ratio to its 






Figure 5: Compounds 3d2 through 3g5 
Figure 5 shows an initial screening of compounds 3d2 through 3g5 at 10µM with DMSO treated cells, live cells, and 





Figure 6: Compounds 1a1 through 1d10 
Figure 6 shows an initial screening of compounds 1a1 through 1d10 at 10µM with DMSO treated cells, live cells, and 





Figure 7: Compounds 1d1 through 1h1 
Figure 7 shows an initial screening of compounds 1d1 through 1h1 at 10µM with DMSO treated cells, live cells, and 




In Figure 7, compound 1e12 was also noted as a candidate for the next screening at lower 
concentrations due to its lower ratio of PC-3 over the DMSO-only treated PC-3 cells. NIH-3T3 
cells shared a ratio similar to their live and vehicle controls, while BPH-1 cells had a ratio of 
approximately 0.6 in comparison to its live and vehicle ratios of 0.8 and 1, respectively. 1g6 was 
another candidate, since it showed ratios for PC-3 and BPH-1 cells (at approximately 0.3 and 





Figure 8: Compounds 4a1 through 4d1 
Figure 8 shows an initial screening of compounds 4a1 through 4d1 at 10µM with DMSO treated cells, live cells, and 




In Figure 8, compound 4b3 was noted as a candidate for the next screening at lower 
concentrations due to its lower ratio of PC-3 over the DMSO-only treated PC-3 cells. BPH-1 and 






Figure 9: Compounds 4d2 through 4g2 
Figure 9 shows an initial screening of compounds 4d2 through 4g2 at 10µM with DMSO treated cells, live cells, and 





Figure 10: Compounds a1 through d3 
Figure 10 shows an initial screening of compounds a1 through d3 at 10µM with DMSO treated cells, live cells, and dead 





Figure 11: Compounds d4 through g6 
Figure 11 shows an initial screening of compounds d4 through g6 at 10µM with DMSO treated cells, live cells, and dead 





Figure 12: Compounds 101-3g6 through 1h12. 
Figure 12 shows an initial screening of compounds 101-3g6 through 1h12 at 10µM with DMSO treated cells, live cells, 





Figure 13: Compounds 3a2 through 4g7 
Figure 13 shows an initial screening of compounds 3a2 through 4g7 at 10µM with DMSO treated cells, live cells, and 





In Figure 13, 3a6 was noted as a candidate for the next screening at lower concentrations 
due to the ratio value of PC-3, which was approximately 0.37, as opposed to the ratio obtained 
from the live cells, which was approximately 0.6. The BPH-1 ratio for this compound was 
approximately 0.49, as opposed to 0.68 for its live control. The NIH-3T3 ratio for this compound 





Figure 14: Compounds 2a1 through 2d2 
Figure 14 shows an initial screening of compounds 2a1 through 2d2 at 10µM with DMSO treated cells, live cells, and 




In Figure 14, 2c3 was chosen as a candidate for the next screening as a result of its lower 
PC-3 ratio in relation to its live and vehicle controls. The BPH-1 ratio for this compound was 




Heat Map and Clustering 
 
Figure 15: Heat Map of Initial Screening 
Figure 15 shows a complete heat map visualization from clustering of the initial screening 
ratios that were calculated after normalization to the DMSO controls.  
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In Figure 15, the lightest spectrum of green coloring signals inhibition of cells, black coloring 
signals no inhibition or growth of cells, and the lightest spectrum of red coloring signals growth 






Figure 16 Zoomed-in Heat Map of Initial Screening 
 Figure 16 shows a zoomed-in visualization of selections of the complete heat map 
with clusters of the initial screening with 511 compounds and the cell lines: PC-3, BPH-1, 




For Figure 16, green indicates inhibition of cells, black indicates no inhibition or growth 
of cells, and red indicates growth of cells. Nine compounds (labeled with a red box) were chosen 
for a second screening. Compounds 5b7, 1e12, 4b3, and d3 exhibited inhibition of PC-3 and no 
inhibition or growth of BPH-1 or NIH-3T3, and compounds 1g6, 3a6, 3c1, 2b2, 2c3 exhibited 




Selected Compound Testing at Lower Concentrations 
Table 1: Percent Inhibition 
 
Table 1 displays the percent inhibition that was calculated for all compounds and for each 
cell line from the initial screening. 
Compound % Inhibition Compound % Inhibition Compound % Inhibition
P1 5b7 84.4 5b7 43.2 5b7 26.7
P7 1e 12 83.8 1e 12 48.1 1e 12 -34.1
P7 1g6 81.0 1g6 82.2 1g6 -25.4
P8 4b3 72.3 4b3 15.6 4b3 -24.1
P13 3a6 71.0 3a6 60.9 3a6 -24.3
P4 3c1 62.2 3c1 53.2 3c1 -8.8
P2 2b2 61.9 2b2 57.6 2b2 -63.2
P14 2c3 58.6 2c3 55.2 2c3 -70.5






Nine compounds were selected from 511 based on two categories. The first category, 
labeled in green, represents compounds that exhibit high percent inhibition for PC-3 cells, low to 
moderate percent inhibition for BPH-1 cells, and very low percent inhibition for NIH-3T3 cells. 
The second category, labeled in yellow, represents compounds that exhibit high percent 
inhibition for PC-3 cells, high percent inhibition for BPH-1 cells, and very low percent inhibition 
for NIH-3T3 cells.  
 The following graphs show the ratio to the DMSO-only treated control values for these 9 
selected compounds at the screening of concentrations at 10µM, 5µM, 2.5µM, 1.25µM, and 






Figure 17: Second Screening: 5b7 through 2b2, Trial 1 
Figure 17 shows the first trial of the second screening of compounds 5b7 through 2b2 at 10µM, 5µM, 2.5µM, 1.25µM, 




After 9 compounds were selected based on the previously mentioned categories of 
inhibition, these 9 compounds were further tested at the concentrations of 10µM, 5µM, 2.5µM, 
1.25µM, and 625nM to check for specificity. The cells were incubated for 72 hours. Figure 16 
shows compounds 5b7 through 2b2, with data labels representing the ratio of actual absorbance 
to DMSO-only treated cells. This test was conducted twice from two different cell populations 
and this graph represents the first population, trial 1. Figure 18 shows the same compounds 
utilizing a second population of cells, trial 2. Figures 19 and 20 show compounds 2c3 and d3 





Figure 18: Second Screening: 5n7 through 2b2, Trial 2 
Figure 18 shows the second trial of the second screening of compounds 5b7 through 2b2 at 10µM, 5µM, 2.5µM, 1.25µM, 




Figure 19: 2c3 and d3, Trial 1 






Figure 20: 2c3 and d3, Trial 2. 





IC50 Analysis (µM) 
Table 2: IC50 Values 
 
For Table 2, IC50 values were calculated with the observed absorbance values from the 





After the average IC50 values were calculated, four compounds with low IC50 values were 
observed: 1g6, 3a6, 2b2, and 2c3. Their respective IC50 values were 7.7µM, 9.0µM, 9.6µM, and 
9.2µM. These values indicate the minimum concentrations needed in order to obtain 50% 





Table 3: Lipinski Values 
 
Table 3 shows the structures of the four selected compounds with IC50 values under 10µM 
that were drawn and the molecular weight, clogp, number of hydrogen donors and 
acceptors, and the total polar surface area were calculated to make sure that these 
compounds fell within the Lipinski Rules.  
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According to Lipinski’s rules, the molecular weight must remain below 500 daltons, the 
clogp must remain below 5, the number of hydrogen donors must remain below 5, the hydrogen 
bond acceptors must remain below 10, and the total polar surface area must remain below 140 






 After conducting an initial screening of 511 compounds derived from the ASINEX 
BioCore library, nine compounds were selected as candidates for a second screening at lower 
concentrations based on their percent inhibition of the three cell lines in order to study their 
potential as viable drugs against prostate cancer. Four of these nine compounds were selected 
based on their IC50 values against PC-3 cells, and all four of this values were lower than 10µM. 
The four compounds, labeled 1g6, 3a6, 2b2, and 2c3, had respective average IC50 values of 
7.7µM, 9.0µM, 9.6µM, and 9.2µM. All four drugs followed Lipinski’s rules, which indicates 
that further studies may be performed due to the fact that they meet some of the guidelines 
necessary to become orally ingested. 
Scaffolds and Previous Assays 
 Two of the four compounds selected from the second screening showed previous assays 
conducted in search of inhibitory effects in the PubChem BioAssay database. Compounds 3a6 
and 2c3 showed no previously known scaffolds and no documented assays per PubChem, 
suggesting that further studies need to be performed to test for inhibitory effects against prostate 
cancer. Compound 2b2 was shown to be inactive against the strain H37rv of Mycobacterium 
tuberculosis (AID:1949 from the Southern Research Institute) and minimally active against two 
strains of Plasmodium falciparum (AID: 449707 from the European Bioinformatics Institute). 
Compound 1g6 was shown to be inactive against the CapD enzyme of Bacillus anthracis, which 
produces amide bonds with peptidoglycan cross-bridges in order to anchor capsular material 
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inside its cell wall envelope (AID: 492967 from the ICCB-Longwood/NSRB Screening Facility 
at Harvard Medical School). It was also shown to be inactive against human Hsp70, which are a 
family of heat shock proteins expressed that play a significant part in protein folding and in 
protection from cellular stress (AID: 583 from the Burnham Center for Chemical Genomics). 
Compound 1g6 was also shown to be inactive against HIV Rnase H in a cell-free assay. Despite 
this recorded lack of inhibitory effects, there have not been any known assays of any possible 
inhibitory effects compounds 2b2 and 1g6 have against prostate cancer or any other forms of 
cancer. Therefore further assays need to be performed to seek inhibition of prostate cancer and 
other cancers.  
Conclusion and Future Directions 
 The compounds selected in this study may be used in the identification of inhibition of 
cellular processes for cell culture-based experiments. It would be important to repeat and 
optimize the initial and second screenings that were conducted in this experiment. After 
repetition and optimization, it would be useful to find the specific processes that are inhibited, 
and an evaluation must be completed to observe which process is plugged by each of these 
compounds. The compounds should be analyzed for any specific character, and knowledge of 
their mechanism of action can be obtained. The pharmacokinetics of these compounds must be 
studied, and an ADME (absorption, distribution, metabolism, and excretion) profile studied, 
since each characteristic influences the drug levels and kinetics of drug exposure to tissues and 
also affects the effectiveness and action of the compound as potential medication. In the future, 
animal testing may be conducted. If inhibition is still observed in vivo, the compounds may be 
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modified for an improved compound and the IC50 values of the compounds may fall within a 
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